RARE: Ultragenyx Pharmaceutical Inc. Net Sales Margin

Brandmark of Ultragenyx Pharma (RARE)

Ultragenyx Pharmaceutical is building a closed ecosystem for rare disease therapies via mRNA platforms. Sales margins demonstrate the effectiveness of this strategy, with -71.80 representing the latest metric reading. Revenue is based on the commercialization of approved molecules and patent protection. Demand for orphan drugs remains consistently high and high-margin due to the lack of alternative treatment methods.

Ultragenyx Pharmaceutical (RARE) - Net Sales Margin from 07/04/2022 to 11/20/2026

Analytical breakdowns and data insights for company Ultragenyx Pharma (RARE)

- market value and analyst target forecast:
Initial company analysis:Ultragenyx Pharmaceutical Inc. - RARE
Manufactured product of Ultragenyx Pharmaceutical Inc.

To objectively evaluate the issuer, it is essential to understand the net profit margin, which determines the proportion of profit remaining from revenue after deducting all operating and tax expenses. By analyzing the average sales margin, an investor can gauge cost management efficiency, which is critical for Ultragenyx Pharmaceutical (RARE) due to the high concentration of resources allocated to costly R&D in the field of gene therapy for rare diseases.

Main competitors

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Company Sales Margin Beam Therapeutics (BEAM)|SRPT: Return on Sales by Net Profit|Net Margin Twist Bioscience|TXG (10x Genomics) - Return on Sales by Net Profit|Intellia Therapeutics, Inc. (NTLA) - Net Sales Margin|Net Margin Stoke Therapeutics Inc|BLFS: Net Profit Rate|Return on Sales by Net Profit WVE (Wave Life Sciences Corp)|Company Sales Margin Maze Therapeutics Corp|Sionna Therapeutics Inc - Return on Sales by Net Profit|PRME (primemedicine.com) - Net Profit Margin|TSHA - Net Margin|QURE (uniQure) - Net Return on Sales|MeiraGTx Corp (MGTX) - Net Margin|Regenxbio - Net Profit Rate|Net Margin solidbio.com|Net Margin ocugen.com OCGN|Net Sales Margin PACB|Benitec - Net Return on Sales|Net Margin Design Therapeutics DSGN|Net Sales Margin Rocket Pharmaceuticals RCKT|Net Profit Margin 4D Molecular Corp|LXEO: Net Margin|KRRO (Korro Bio, Inc) - Return on Sales by Net Profit|Editas Medicine (EDIT) - Net Sales Margin|Net Margin Silence Therapeutics Inc.|Net Return on Sales PRQR (proqr.com)|Net Margin Codexis Bio (CDXS)|Net Sales Margin sangamo.com (SGMO)|Net Margin nautilus.bio NAUT|Company Sales Margin Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Net Sales Margin|GBIO - Net Sales Margin|BOLD: Net Sales Margin|Net Return on Sales XCUR|Net Margin Imunon|Phio Pharmaceuticals - Net Profit Margin|Net Margin Mustang Bio, Inc. (MBIO)|Company Sales Margin TransCode Therapeutics, Inc.|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX